Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07545122 |
| Title | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers (CT-202) |
| Acronym | CT-202 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Context Therapeutics Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Tasman Oncology Research | Gold Coast | Queensland | Australia | Details | ||
| Calvary Mater Hospital Newcastle | Newcastle | Queensland | Australia | Details | ||
| Linear Clinical Research | Perth | Western Australia | Australia | Details |